McDavid Stilwell - 09 Jun 2021 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Financial Officer
Signature
/s/ McDavid Stilwell
Issuer symbol
CHRS
Transactions as of
09 Jun 2021
Net transactions value
+$49,668
Form type
4
Filing time
10 Jun 2021, 16:35:47 UTC
Next filing
19 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Purchase $49,668 +3,700 +12% $13.42 35,118 09 Jun 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades in prices ranging from $13.415 to $13.4294, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F2 Includes 30,000 restricted stock units.
F3 Includes 1,418 shares acquired on May 14, 2021, pursuant to Issuer's employee stock purchase plan.